High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma

Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of healthcare engineering 2022-02, Vol.2022, p.3565676-12
Hauptverfasser: Tao, Ke, Wei, Zhouxia, Xia, Yan, Zhao, Ruihong, Xu, Hong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue
container_start_page 3565676
container_title Journal of healthcare engineering
container_volume 2022
creator Tao, Ke
Wei, Zhouxia
Xia, Yan
Zhao, Ruihong
Xu, Hong
description Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.
doi_str_mv 10.1155/2022/3565676
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8865998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634512036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</originalsourceid><addsrcrecordid>eNp9kU1vGyEQhlHVqonS3HquOFZqnbCwwHKpFFlOYylSrX6c0Zid9VLtggvr5uPXl8RO1F7KhQEePTPoJeRtxc6qSspzzjg_F1JJpdULcsxZzWZcMPPyqeZGHpHTnH-ysoQRdSVekyMhOedNI47J_ZXf9PTb8uvqgi5utwlz9jHQVcLWuynTVYypnOImxOwzhdDSeUwJB5gw0xs_9XQ5jruAdBk6P0zp8d4XA0wew3RgFjlue9ggDHQOyfkQR3hDXnUwZDw97Cfkx-Xi-_xqdv3l83J-cT1zNWfTjDMNa2UUYmsa3joDqtOtqDoNWCE0GtGVL6-NERoFdqXWDa9Bas3QSSdOyKe9d7tbj9i6MlWCwW6THyHd2Qje_vsSfG838bdtGiWNaYrg_UGQ4q8d5smOPjscBggYd9lyJWpZcSZUQT_uUZdizgm75zYVsw-J2YfE7CGxgr_7e7Rn-CmfAnzYA70PLdz4_-v-AMrJoCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634512036</pqid></control><display><type>article</type><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong</creator><contributor>Jain, Deepak Kumar</contributor><creatorcontrib>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong ; Jain, Deepak Kumar</creatorcontrib><description>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</description><identifier>ISSN: 2040-2295</identifier><identifier>EISSN: 2040-2309</identifier><identifier>DOI: 10.1155/2022/3565676</identifier><identifier>PMID: 35222883</identifier><language>eng</language><publisher>England: Hindawi</publisher><subject>Antigens, Differentiation ; Carcinoma ; Esophageal Neoplasms ; Humans ; Prognosis ; Receptors, Immunologic</subject><ispartof>Journal of healthcare engineering, 2022-02, Vol.2022, p.3565676-12</ispartof><rights>Copyright © 2022 Ke Tao et al.</rights><rights>Copyright © 2022 Ke Tao et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</citedby><cites>FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</cites><orcidid>0000-0003-2798-2078</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865998/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865998/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35222883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Jain, Deepak Kumar</contributor><creatorcontrib>Tao, Ke</creatorcontrib><creatorcontrib>Wei, Zhouxia</creatorcontrib><creatorcontrib>Xia, Yan</creatorcontrib><creatorcontrib>Zhao, Ruihong</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><title>Journal of healthcare engineering</title><addtitle>J Healthc Eng</addtitle><description>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</description><subject>Antigens, Differentiation</subject><subject>Carcinoma</subject><subject>Esophageal Neoplasms</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Receptors, Immunologic</subject><issn>2040-2295</issn><issn>2040-2309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU1vGyEQhlHVqonS3HquOFZqnbCwwHKpFFlOYylSrX6c0Zid9VLtggvr5uPXl8RO1F7KhQEePTPoJeRtxc6qSspzzjg_F1JJpdULcsxZzWZcMPPyqeZGHpHTnH-ysoQRdSVekyMhOedNI47J_ZXf9PTb8uvqgi5utwlz9jHQVcLWuynTVYypnOImxOwzhdDSeUwJB5gw0xs_9XQ5jruAdBk6P0zp8d4XA0wew3RgFjlue9ggDHQOyfkQR3hDXnUwZDw97Cfkx-Xi-_xqdv3l83J-cT1zNWfTjDMNa2UUYmsa3joDqtOtqDoNWCE0GtGVL6-NERoFdqXWDa9Bas3QSSdOyKe9d7tbj9i6MlWCwW6THyHd2Qje_vsSfG838bdtGiWNaYrg_UGQ4q8d5smOPjscBggYd9lyJWpZcSZUQT_uUZdizgm75zYVsw-J2YfE7CGxgr_7e7Rn-CmfAnzYA70PLdz4_-v-AMrJoCA</recordid><startdate>20220216</startdate><enddate>20220216</enddate><creator>Tao, Ke</creator><creator>Wei, Zhouxia</creator><creator>Xia, Yan</creator><creator>Zhao, Ruihong</creator><creator>Xu, Hong</creator><general>Hindawi</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2798-2078</orcidid></search><sort><creationdate>20220216</creationdate><title>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</title><author>Tao, Ke ; Wei, Zhouxia ; Xia, Yan ; Zhao, Ruihong ; Xu, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-207ab696eed982dc9a6f7d31f7ae1ea87eec230b9937e3ef2307824a5770ec5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens, Differentiation</topic><topic>Carcinoma</topic><topic>Esophageal Neoplasms</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Receptors, Immunologic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tao, Ke</creatorcontrib><creatorcontrib>Wei, Zhouxia</creatorcontrib><creatorcontrib>Xia, Yan</creatorcontrib><creatorcontrib>Zhao, Ruihong</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of healthcare engineering</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tao, Ke</au><au>Wei, Zhouxia</au><au>Xia, Yan</au><au>Zhao, Ruihong</au><au>Xu, Hong</au><au>Jain, Deepak Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma</atitle><jtitle>Journal of healthcare engineering</jtitle><addtitle>J Healthc Eng</addtitle><date>2022-02-16</date><risdate>2022</risdate><volume>2022</volume><spage>3565676</spage><epage>12</epage><pages>3565676-12</pages><issn>2040-2295</issn><eissn>2040-2309</eissn><abstract>Background. Signal regulatory protein alpha (SIRPA) is an inhibitory receptor expressed in macrophages and a potential therapeutic target in cancers. This study aims to investigate the functional role of SIRPA in esophageal carcinoma (ESCA). Methods. Based on the Oncomine and The Cancer Genome Atlas (TCGA) database, SIRPA expression and clinical value were determined. Gene set enrichment analysis (GSEA) was performed to predict the mechanism underlying the oncogene role of SIRPA. Spearman’s correlation analysis was used to analyze the effects of SIRPA on the molecular relationship and immune landscape. Results. SIRPA was highly expressed across Oncomine and TCGA databases and correlated with poor overall survival and disease-specific survival. There was an expression difference among clinical characteristics. Functional annotation showed that cancer-related biological function and pathways were enriched in the high SIRPA expression group. Besides, SIRPA strongly and extensively affected the immune infiltrates. Conclusion. SIRPA might be an oncogene and a target of immunotherapy in ESCA.</abstract><cop>England</cop><pub>Hindawi</pub><pmid>35222883</pmid><doi>10.1155/2022/3565676</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2798-2078</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2040-2295
ispartof Journal of healthcare engineering, 2022-02, Vol.2022, p.3565676-12
issn 2040-2295
2040-2309
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8865998
source MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
subjects Antigens, Differentiation
Carcinoma
Esophageal Neoplasms
Humans
Prognosis
Receptors, Immunologic
title High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T14%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20SIRPA%20Expression%20Predicts%20Poor%20Prognosis%20and%20Correlates%20with%20Immune%20Infiltrates%20in%20Patients%20with%20Esophageal%20Carcinoma&rft.jtitle=Journal%20of%20healthcare%20engineering&rft.au=Tao,%20Ke&rft.date=2022-02-16&rft.volume=2022&rft.spage=3565676&rft.epage=12&rft.pages=3565676-12&rft.issn=2040-2295&rft.eissn=2040-2309&rft_id=info:doi/10.1155/2022/3565676&rft_dat=%3Cproquest_pubme%3E2634512036%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634512036&rft_id=info:pmid/35222883&rfr_iscdi=true